ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alnylam And Tekmira Ink RNAi Delivery Pact

by Michael McCoy
August 10, 2009 | APPEARED IN VOLUME 87, ISSUE 32

Alnylam Pharmaceuticals and Canada's Tekmira Pharmaceuticals have formed a research collaboration focused on the discovery of cationic lipids and lipid nanoparticles for the delivery of RNAi therapeutics. Both companies are already advancing RNAi drugs that use Tekmira's stable nucleic acid lipid particle delivery technology. Research will be funded by Alnylam and conducted by scientists at the University of British Columbia and at a newly formed company called AlCana Technologies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment